Pure Global AI
NCT06317428Recruiting

NT-proBNP Levels During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.

Change in Serum Levels of NT-proBNP During Triple Therapy With Formoterol/Glycopyrrolate/Budesonide in Patients With COPD.
Istituto Nazionale di Ricovero e Cura per AnzianiClinicalTrials.gov
Verified
Study focus
Disease/Condition
COPD
Study type
Observational
Sponsor & location
Primary sponsor
Istituto Nazionale di Ricovero e Cura per Anziani
Location
Ancona,Osimo, Italy
Timeline & enrollment
Phase
N/A
Start date
Jun 28, 2022
End date
Dec 31, 2025
Enrollment
29 participants
Primary outcome

Change in serum NT-pro-BNP levels

Summary

Observational prospective study to evaluate serum NT-proBNP levels in a population of COPD
 patients three months after the iniation of triple inhaled
 formoterol/glycopyrrolate/budesonide therapy.

ICD-10 classifications
Chronic obstructive pulmonary disease, unspecifiedOther chronic obstructive pulmonary diseaseOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedPulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06317428
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06317428 through Pure Global AI's free database. This phase not specified trial is sponsored by Istituto Nazionale di Ricovero e Cura per Anziani and is currently Recruiting. The study focuses on COPD. Target enrollment is 29 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.